Tumor stromal barriers to the success of adoptive T cell therapy

Cancer Immunology, Immunotherapy

Volumn 57, Issue 2, 2008, Pages 281-283

  Phan, Vy ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DONOR LYMPHOCYTE INFUSION; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE CLONE; LYMPHOCYTE TRANSFER; METASTASIS; MICROENVIRONMENT; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE; TUMOR; TUMOR LOCALIZATION;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 36348975149     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0356-6     Document Type: Note

References (21)

1. Cheever MA, Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177-194
2. Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25:243-265
3. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061
4. Chen A et al (2007) Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 67(3):1291-1298
5. Yee C et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168-16173
6. Dudley ME et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2457
7. Morgan RA et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126-129
8. Bernhard H, et al (2007) Adoptive transfer of autologous, HER-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother (in press)
9. Blankenstein T (2005) The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17(2):180-186
10. Ho WY et al (2003) Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5):431-437
11. Thanarajasingam U, et al (2007) Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 67(1):300-308
12. Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294-298
13. Dunn GP et al (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6(7):722-729
14. Pages F et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666
15. Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964
16. Zhang L et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213
17. Chen Q et al (2006) Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 7(12):1299-1308
18. Skitzki J, Chen Q, Fisher D, Muhitch J, Wang W, Repasky E, Evans S (2007) Systemic thermal therapy improves effector cell trafficking to sites of tumor and clinical outcome. Abstract, STM Annual Meeting
19. Zhang B et al (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204(1):49-55
20. Marijt WA et al (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100(5):2742-2747
21. Bollard CM et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200(12):1623-1633